Search the Bulletin

Joseph Turner ’73

Joseph Turner ’73 was named to the board of directors of Sophiris Bio Inc., a biopharmaceutical companyJoe_Turner_April_2013.jpg that is developing a clinical-stage, targeted treatment for symptoms of benign prostatic hyperplasia (enlarged prostate). Turner has more than 25 years of financial management experience in the biotech and pharmaceutical industries. In addition to serving on Swarthmore’s Board of Managers, he is on the board of directors and is chair of the audit committees for Kythera Biopharmaceuticals, Alexza Pharmaceuticals, and Corcept Therapeutics. From 1999 to 2006, Turner was chief financial officer at Myogen Inc. He is also on the board of a private biotech company BioClin Therapeutics Inc. He was vice president of finance at Centaur Pharmaceuticals, 1997–1999, and at Cortech Inc., 1992–1997.

Comments are closed.